181 related articles for article (PubMed ID: 15972483)
21. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
Younis S; Faber BW; Kocken CHM; Remarque EJ
BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.
Stowers AW; Kennedy MC; Keegan BP; Saul A; Long CA; Miller LH
Infect Immun; 2002 Dec; 70(12):6961-7. PubMed ID: 12438375
[TBL] [Abstract][Full Text] [Related]
23. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
Malar J; 2011 May; 10():108. PubMed ID: 21529376
[TBL] [Abstract][Full Text] [Related]
24. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.
Kocken CH; Withers-Martinez C; Dubbeld MA; van der Wel A; Hackett F; Valderrama A; Blackman MJ; Thomas AW
Infect Immun; 2002 Aug; 70(8):4471-6. PubMed ID: 12117958
[TBL] [Abstract][Full Text] [Related]
25. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.
Remarque EJ; Roestenberg M; Younis S; Walraven V; van der Werff N; Faber BW; Leroy O; Sauerwein R; Kocken CH; Thomas AW
PLoS One; 2012; 7(6):e38898. PubMed ID: 22768052
[TBL] [Abstract][Full Text] [Related]
26. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris.
Faber BW; Remarque EJ; Kocken CH; Cheront P; Cingolani D; Xhonneux F; Jurado M; Haumont M; Jepsen S; Leroy O; Thomas AW
Vaccine; 2008 Nov; 26(48):6143-50. PubMed ID: 18804135
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
28. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
29. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
Miura K; Herrera R; Diouf A; Zhou H; Mu J; Hu Z; MacDonald NJ; Reiter K; Nguyen V; Shimp RL; Singh K; Narum DL; Long CA; Miller LH
Infect Immun; 2013 May; 81(5):1491-501. PubMed ID: 23429537
[TBL] [Abstract][Full Text] [Related]
30. Effect of codon optimization on expression levels of a functionally folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems.
Yadava A; Ockenhouse CF
Infect Immun; 2003 Sep; 71(9):4961-9. PubMed ID: 12933838
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
32. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
Biswas S; Dicks MD; Long CA; Remarque EJ; Siani L; Colloca S; Cottingham MG; Holder AA; Gilbert SC; Hill AV; Draper SJ
PLoS One; 2011; 6(6):e20977. PubMed ID: 21698193
[TBL] [Abstract][Full Text] [Related]
33. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.
Osier FH; Weedall GD; Verra F; Murungi L; Tetteh KK; Bull P; Faber BW; Remarque E; Thomas A; Marsh K; Conway DJ
Infect Immun; 2010 Nov; 78(11):4625-33. PubMed ID: 20732997
[TBL] [Abstract][Full Text] [Related]
34. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.
Kusi KA; Faber BW; Riasat V; Thomas AW; Kocken CH; Remarque EJ
PLoS One; 2010 Nov; 5(11):e15391. PubMed ID: 21082025
[TBL] [Abstract][Full Text] [Related]
35. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.
Polley SD; Mwangi T; Kocken CH; Thomas AW; Dutta S; Lanar DE; Remarque E; Ross A; Williams TN; Mwambingu G; Lowe B; Conway DJ; Marsh K
Vaccine; 2004 Dec; 23(5):718-28. PubMed ID: 15542195
[TBL] [Abstract][Full Text] [Related]
36. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.
Faber BW; Younis S; Remarque EJ; Rodriguez Garcia R; Riasat V; Walraven V; van der Werff N; van der Eijk M; Cavanagh DR; Holder AA; Thomas AW; Kocken CH
Infect Immun; 2013 May; 81(5):1479-90. PubMed ID: 23429538
[TBL] [Abstract][Full Text] [Related]
37. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
[TBL] [Abstract][Full Text] [Related]
38. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.
Miura K; Zhou H; Muratova OV; Orcutt AC; Giersing B; Miller LH; Long CA
Infect Immun; 2007 Dec; 75(12):5827-36. PubMed ID: 17923516
[TBL] [Abstract][Full Text] [Related]
39. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria.
Srinivasan P; Ekanem E; Diouf A; Tonkin ML; Miura K; Boulanger MJ; Long CA; Narum DL; Miller LH
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10311-6. PubMed ID: 24958881
[TBL] [Abstract][Full Text] [Related]
40. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
Darko CA; Angov E; Collins WE; Bergmann-Leitner ES; Girouard AS; Hitt SL; McBride JS; Diggs CL; Holder AA; Long CA; Barnwell JW; Lyon JA
Infect Immun; 2005 Jan; 73(1):287-97. PubMed ID: 15618165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
